Mild cognitive impairment in amyotrophic lateral sclerosis: current view

Area of Science:

• Neuroscience
• Neurology
• Cognitive Science

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily affecting motor neurons.
• Cognitive dysfunction, including mild cognitive impairment (MCI), is a significant non-motor symptom in ALS patients.
• MCI in ALS impacts patient and caregiver burden and can precede motor symptom onset.

Purpose of the Study:

• To investigate the cognitive deficits in ALS patients.
• To explore the neuroimaging correlates of cognitive impairment in ALS.
• To identify potential early diagnostic biomarkers and therapeutic targets for MCI in ALS.

Main Methods:

• Neuropsychological assessments to evaluate cognitive domains.
• Neuroimaging techniques (MRI, PET) to analyze brain structure and function.
• Analysis of cerebrospinal fluid and serum for potential biomarkers (e.g., neurofilament light/heavy chain, GFAP).

Main Results:

• ALS patients exhibit deficits in verbal fluency, language, executive function, attention, and memory.
• Neuroimaging reveals frontal/temporal cortical atrophy, white matter abnormalities, and reduced volume in the amygdala and thalamus.
• Neuronal loss and TDP-43 deposition correlate with disrupted frontostriatal and frontotemporo-limbic connectivities.

Conclusions:

• Cognitive impairment is a key feature of ALS, linked to specific brain structural and connectivity changes.
• Early diagnosis of MCI in ALS may be facilitated by fluid biomarkers and brain connectivity signatures.
• Understanding the pathophysiology of MCI in ALS is crucial for developing targeted treatments to delay or prevent disease progression.